Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 22NIH 20NETWORK 6INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 5Thoracic 4Breast 4Genitourinary 3Gastrointestinal 3Sarcoma 2Dermatologic 2Tumor-Agnostic 1Other neoplasm 1Head & Neck 1Endocrine 1

Conditions

Sarcoma, Endometrial Stromal 1Leiomyosarcoma 1Leiomyoma 1Adrenocortical Adenoma 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Biopsy × Sarcoma × Clear all
NCT04214457 2021-09-05

MYOSARC

Igenomix

Unknown
1,000 enrolled
Sarcoma

Leiomyoma, Leiomyosarcoma

NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡